Skip to content

High-volume HDF has clinical advantages. It is easy to carry out and brings economic value1. But most of all, patients may live longer, as indicated by the CONVINCE study, which showed a 23% reduction in the risk of mortality in the HDF vs. HD group².

Fresenius Medical Care published form 20-F for the fiscal year 2023

Latest News

Fresenius Medical Care published form 20-F for the fiscal year 2023
The Benefits of Home Dialysis - How to Thrive >

Health & Wellness

The Benefits of Home Dialysis - How to Thrive

For Investors

February 20, 2024
Full Year 2023 results
The replay and media material of the Fresenius Medical Care 2024 Annual Press Conference regarding full year earnings for 2023. >

Events

The replay and media material of the Fresenius Medical Care 2024 Annual Press Conference regarding full year earnings for 2023.
Positive Purchasing Power >

Together

Positive Purchasing Power
“How can we offer our patients the best possible treatment?” >

Research

“How can we offer our patients the best possible treatment?”

Healthcare Professionals

Products, therapies and services for Healthcare Professionals

Learn more

Patients & Families

Patients & Families

Learn more

WHO WE ARE

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment.

Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with its core business, the Renal Care Continuum, the company focuses on expanding in complementary areas and in the field of critical care.

~ 52 M

TREATMENTS

> 332,000

PATIENTS SERVED

~ 4,000

CLINICS

~ 40

PRODUCTION SITES

~ 120,000

EMPLOYEES